JNCCN 360 - Immunotherapy

Advertisement

Advertisement

Alexander M.M. Eggermont, MD, PhD, on Adjuvant Therapy for High-Risk Melanoma

Theresa M. Medina, MD, on Treating Cutaneous Squamous Cell Carcinoma With Cemiplimab-rwlc

Anthony J. Olszanski, MD, RPh, on Cutaneous Melanoma: Adjuvant Systemic Therapy

Recent

Lisocabtagene Maraleucel for Resistant CLL: Phase I Trial Update

Avelumab Plus Axitinib Under Study in Urothelial Cancer

Tiragolumab Combination Treatment Granted Breakthrough Therapy Designation in NSCLC

Early Study of Lisocabtagene Maraleucel Plus Ibrutinib in Resistant CLL

Published

Medical Literature

Is Immunotherapy Safe for Patients With Myeloma and HBV Infection?

Pembrolizumab Plus T-Cell Inducer Under Study in Triple-Negative Breast Cancer

Extended Follow-up From KEYNOTE-426: Pembrolizumab Plus Axitinib in Kidney Cancer

Atezolizumab Plus VEGF Inhibition in Stage IV Lung Cancer

Ongoing

Modest Responses With Immunotherapy Combo for Advanced Ovarian Cancer

Emerging Considerations in Triple-Negative Breast Cancer: Focus on Immunotherapy

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

ClinicalTrials.gov Immunotherapy

Center for Immunotherapy Clinical Research Trials

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

NCCN Resources

Copyright © 2021 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.